Tourmaline Bio Inc
NASDAQ:TRML
Tourmaline Bio Inc
NASDAQ:TRML
Price:
13.77 USD
1.85%
Market Closed
Updated:
Jun 1, 2024
P/E
Price to Earnings
Price to Earnings
-16.7
Current
-14.3
Median
24.7
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-16.7
Market Cap
/
550.1m
Net Income
-32.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Tourmaline Bio Inc
NASDAQ:TRML
|
550.1m USD | -16.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 47.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 43.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 29.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 28 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 36.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 165.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | -9.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 28.1 | |
| IE |
|
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 60.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-7.2
2-Years Forward
P/E
-6.6
3-Years Forward
P/E
-5.7
You don't have any saved screeners yet
